The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the most undervalued biotech stocks to buy right now. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on April 13 a collaboration with Telix Pharmaceuticals Limited aimed at the joint development and commercialization of next-generation radiopharmaceutical therapies. Management stated that the collaboration brings together Regeneron Pharmaceuticals’ (NASDAQ:REGN) biologics expertise, including bispecific antibody discovery, with Telix’s radiopharmaceutical development platform, global manufacturing capabilities, and supply chain infrastructure. It further reported that the collaboration will include several solid tumor targets from Regeneron Pharmaceuticals’ (NASDAQ:REGN) portfolio of antibodies, generated from VelocImmune® mice. The agreement also aims at developing radio-diagnostics to support patient selection and treatment response assessment, in line with the two companies’ shared commitment to precision oncology.

The terms of the agreement state that Telix will receive an upfront cash payment of $40 million from Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for access to its radiopharmaceutical manufacturing platform for four initial therapeutic programs. The latter will have the option to expand to include four additional programs with additional upfront payments.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a pharmaceutical company that develops, discovers, and commercializes therapies for several diseases, including cancer, eye disorders, and allergic conditions. It has relied on two primary products to drive top-line growth in the past years: Dupixent and Eylea.

While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.